

Award Number: W81XWH-11-1-0429

TITLE: Microvascular Channel Device to Study Aggressiveness in Prostate Cancer Metastasis

PRINCIPAL INVESTIGATOR: Sayeda Yasmin-Karim

CONTRACTING ORGANIZATION: University of Rochester
Rochester, NY 14611

REPORT DATE: June 2012

TYPE OF REPORT: Annual Summary

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE 01-06-2012		2. REPORT TYPE Annual Summary		3. DATES COVERED 15 May 2011 - 14 May 2012	
4. TITLE AND SUBTITLE Microvascular Channel Device to Study Aggressiveness in Prostate Cancer Metastasis				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-11-1-0429	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Sayeda Yasmin-Karim E-Mail: Sayeda_yasmin-karim@urmc.rochester.edu				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of Rochester Rochester, NY 14627-0140				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT To study circulating prostate cancer cell adhesion behavior and the contribution to distance metastasis of prostate cancer, we applied a dynamic flow-based E-selectin+SDF-1 coated microchannel system to isolate and characterize a subpopulation of adhering prostate cancer cells. We found a positive correlation of cells' aggressiveness with their adhesion/rolling ability. By using this device we then sorted prostate cancer cell lines (PC3 and DU-145) into rolling and floating populations, and tested for their behavior <i>in vitro</i> and <i>in vivo</i> . Results from our <i>in vitro</i> studies found that rolling cancer cells are more aggressive in nature with higher growth rate and invasion and form bigger and more colonies in soft agar and 3D sphere formation assays. To test further <i>in vivo</i> , an orthotopic implantation mouse model is underway. In summary, this flow based device provides a platform for isolating the most dangerous aggressive form of cancer cells which can be used for human patients' peripheral blood for isolating and characterizing and to form a process for customized cancer treatment.					
15. SUBJECT TERMS prostate cancer, metastasis, selectin, circulating, Micro-vascular					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRMC
U	U	U	UU	16	19b. TELEPHONE NUMBER (include area code)

Table of Contents

	<u>Page</u>
Introduction.....	2
Body.....	3
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusion.....	10
References.....	11
Appendices.....	None

INTRODUCTION

Prostate cancer is the second most common cause of male cancer death in the USA. The major cause of cancer patient mortality is metastasis. Recent studies found that epithelial origin cancer cells can undergo epithelial-to-mesenchymal transition (EMT), which plays an important role in metastasis, where the cancer cells gain the genes that can transform them to behave as 'leukocyte like' cells to be transported through the blood stream to their metastatic destinations (1). Like leukocytes, Prostate Cancer (PRCA) cells preferentially adhere and roll on bone marrow endothelial cells (BMECs) (2, 3) where abundant E-selectin is expressed (4), subsequently initiating a cascade of activation events that eventually leads to the invasion, migration, and ultimately development of metastatic tumors (5-7). All of the observations support the notion that prostate cancer adhesion to the BMECs is a key step in the metastasis cascade. Selectin plays a very important role for capturing cancer cells from the blood stream and migrating them to the site of metastasis. (3). Activated prostate cancer cells become firmly adhered through integrin mediated interactions, and finally, the cells migrate across the endothelium under the direction of SDF-1 gradient (3). To study the mechanisms by which prostate cancer cells adhere to vessel endothelial cells, we applied a dynamic flow-based E-selectin coated microchannel system, cylindrical flow chamber. This selectin-mediated system mimics physiological events involved in normal cell trafficking such as recruitment of leukocytes during the inflammatory response and homing of hematopoietic stem cells to the bone marrow (8-10). We successfully established parameters' for the dynamic flow-based E-selectin+SDF-1 coated microtubes, which can capture PRCA cells and allow us to study the circulating tumor cell behavior and its contribution to tumor metastasis. It was concluded that, a tube coated with 40 $\mu\text{g/ml}$ of E-selectin and 10 $\mu\text{g/ml}$ of SDF-1 β with shear stress 1 dyne/cm^2 is the best possible combination to collect the smallest more potent PRCA cells from the tube based circulation model (preliminary data). We used this selectin and SDF-1 β coated micro-urethane tubing system, which mimics pro-metastatic vascular endothelial cell surface, for the capturing of 'rolling/adhesion/attached' group of PRCA cells. We found that the 'rolling/adhesive/attached' group of cells possess more aggressive and stem cell type characteristics compared to the 'floating' in our *in vitro* assay. In summary, our experimental *in vitro* data confirmed that cell rolling is a critical step in controlling cancer metastasis, and this novel flow-based device provides a system to capture and enrich metastatic cancer cells from the circulation. So further evaluation is necessary not only to identify the pathways/genes that are responsible for cancer metastasis, but also to provide a pure population for preclinical drug screening. It opens up a process for customized cancer treatment which can have more potent action and also reduce the disadvantage of multiple drug side effects.

BODY

We worked on Task 1 and Task 2 in this period of time and accomplished the following areas.

We submitted task 1 in our work statement as:

Task 1: Correlation of cancers' aggressiveness with their adhesion /rolling capacity in static and dynamic flow-based status (timeframe: months 1-12).

1a: Determination of cell rolling capacity in a dynamic state (timeframe: months 1-12).

1b: Determination of cell adhesion ability in a static condition (timeframe: months 1-8).

1c: Determination of cell metastatic behavior *in vitro* (timeframe: months 1-12).


Accomplishment of Task 1:

Using a dynamic flow-based system, we analyzed the adhesion/rolling/attached subgroup of LNCaP, CWR22R, and BPH-1 series, and correlate with their aggressiveness. We have shown the rolling capacity of LNCaP and CWR22R series in our preliminary data, and now we continue to analyze the third cell type- BPH-1 series, from nontumorigenic, low grade tumorigenic (BCaPT10) to metastatic (BCaPM10) cell lines. Cells which roll on the E-selectin and SDF-1 β (R and D Co.) coated micro-renathane tube (Braintree Scientific, inc.) were considered as 'rolling/adherent/attached' cells. To perform rolling capacity, determined by rolling cell number and rolling cell velocity, we perfused BCaP10 and BCaPM10 cell lines through 2 separate coated (E-selectin + SDF-1 β) tubes under microscopic guidance. Cells' rolling behavior was video recorded for analysis. In our body, metastatic prone circulating cancer cells tether, roll and ultimately adhere on the endothelial cell surface of the capillary to where the shear stress is low. They then exert from the capillary for distant metastasis (1). *In vitro*, under shear stress the metastatic/aggressive type of prostate cancer cells should roll on the inner surface of the blood vessel mimicking E-selectin/SDF-1 coated tube and eventually adhere. So the rolling/adherent/attached cell number should be higher in more aggressive prostate cancer cells. On the other hand, prostate cancer cells which roll faster would not adhere on the surface; they would roll a few times and ultimately flush away under shear flow. The cells which do not roll at all would be given '0' in rolling velocity.

We defined rolling cells as cells that translated at an average velocity <50% of the calculated free stream velocity for more than 2 seconds while remaining in the field of view [FOV: 432 μm $\times$ 324 μm , using a 20x Plan Fluorite objective, NA 0.40 (Olympus America Inc., Center Valley, PA)]. Rolling cells that interacted with other cells were not included (11). We used shear stress 1 dyne/cm², which is the lowest shear stress in the capillary (12), to analyze BPH-1 series and we found that metastatic subtype BCaPM10 displayed higher rolling cell number as compared to the tumorigenic, low grade BCaPT10. As expected, rolling velocity of the BCaPT10 was higher as compared to the BCaPM10 cells. Next, we compare their invasiveness *in vitro* using BD matrigel coated (BD Bioscience) invasion chamber. We found

that metastatic BCaPM10 cells show higher invasiveness as compared to tumorigenic BCaPT10 cells (Figure 1).

Figure 1



We submitted task 2 in our work statement as:

Task 2: Sorting prostate cancer cells into adhesion (attached) and non-adhesion (floating) subpopulations and comparison of these two populations' metastatic behaviors *in vitro* and *in vivo* (timeframe: months 5-24).

2a: Fractionation of prostate cancer (PRCA) cells based on rolling capacity (timeframe: months 5-20).

2b: Characterization of sorted cells metastatic behavior *in vitro* (timeframe: months 7-18).

2c: Confirmation of metastatic potential on those rolling PRCA cells *in vivo* by the orthotopic injection mice model (timeframe: months 13-24).

Accomplishment of Task 2:

We performed part of the Task 2a & 2b for sorting and analyzing of prostate cancer cell lines. We found that the rolling/adhesive/attached cells are more aggressive and possesses more cancer stem cell characteristics compared to the floating population in our *in vitro* assays.

For sorting prostate cancer cells, PC3 and DU-145 cell lines were used. Each type of cells was infused through the immobilized E-selectin and SDF-1 β coated micro-renalthane tube at 1dyne/cm² shear stress. Rolling/adherent/attached cells were collected separately from non-rolling (floating) cells. All the parameters were tested for the sorted PC3 cells, the same as we did with DU-145 cell line (1dyne/cm² shear stress, and the same concentration of immobilized E-selectin and SDF-1 β). We noticed that PC3 cells have higher adhesiveness to selectin/SDF-1 coated tube as compared to DU-145 cells. The results are described in the following.

Viability testing of Sorted Cells:

To maintain the characteristics of sorted PC3 cells (floating vs. rolling), we collected sorted cells and characterized their behavior *in vitro* and *in vivo* for no more than two passages after sorting. First, cell viability of sorted floating and adhesion cells were determined by trypan blue staining (using Vi-CELL-XR Cell Viability Analyzer, Beckman Coulter). As shown in Table 1, the viability of all three populations is similar, ranging from 96-86%. Interestingly, the adhesion cells exhibit the lowest viability among all three, but the difference is not significant.

Table 1:

	Parental: Before sorting	Floating: After sorting	Rolling: After sorting
Viable cells (%)	96.8	94.4	86.7

Aggressiveness of Sorted cells:

Collected 'rolling' and 'floating' cells were then compared for their aggressiveness *in vitro*, freshly sorted cells were used to perform growth assay (MTT) and invasion assay using BD matrigel invasion chambers (BD Biosciences)) and static adhesion assay on HMEC-1 cells. As shown in Figure 2, rolling/adhesion/attached prostate cancer cells showed higher aggressive behavior than floating cells, where rolling cells have higher proliferation rate by the MTT assay, more invasiveness by invasive chamber assay, and possess more adhesiveness to endothelial HMEC-1 cells by a static adhesion assay.

In addition, we also tested their anchorage independent growth ability by the colony formation assay. As expected, the rolling cells formed more and bigger colonies than floating cells (figure 3). The stem cell characteristics were also compared between floating and rolling cells, due to their potential contribution to metastasis. As shown in Figure 4, the rolling PC3 cells exhibit bigger in size and higher number of 3D-sphere, the standard assay to characterize stem cells.




Figure 3





Figure 4



After seeing these encouraging results *in vitro*, we are now sorting cells and confirm their aggressiveness/metastasis behavior *in vivo* as proposed in Task 2c.

In summary, we have provided evidence showing this flow based E-selectin/SDF coated tube can allow us to sort a small percentage of prostate cancer cells that represent the most dangerous populations in circulation.

After seeing these encouraging results *in vitro*, we concluded that this flow-based device can capture a small population of most aggressive prostate cancer cells in the circulation. We now continue our efforts to confirm if this remains the same *in vivo* orthtopic xenograft mouse model as proposed in Aim 2/ Task 2c.

Key Research Accomplishments

- Establishment of an *in vitro* system to analyze the rolling behavior of prostate cancer cell lines.
- Establishment of a sorting system of prostate cancer cells based on their rolling behavior: rolling/adhesion cells (<5%) and floating cells (>95%).
- Correlation of prostate cancer cells' aggressiveness with their rolling behavior.
- In vitro characterization of sorted prostate cancer cells (floating vs. rolling) behavior and aggressiveness.

Reportable Outcomes

- Participated in a poster session of prostate cancer basic research in the American Urological Association (AUA) annual meeting in Atlanta, Georgia May 19 – May 23, 2012 (please see the appendix for documents).

CONCLUSION:

We used this selectin and SDF-1 coated micro-renathane tubing system, to capture the 'rolling/adhesion/attached' subpopulation of prostate cancer cells, such as PC-3 and DU145 cells under constant flow (shear stress 1 dyne/cm²). Based on their adhesion ability, prostate cancer cells were sorted into: rolling/adhesion/attached fraction which contains potentially a more aggressive cells population, and non-adhesion/floating fraction which were less aggressive subpopulation. We found that the 'rolling/adhesive' cells are more aggressive in nature, as compared to the 'floating' cancer cells by *in vitro* assays including cell proliferation assay (MTT assay), invasion Assay, and static adhesion assay on HMEC-1 cells and anchorage-independent assay (sulf agar colony formation assay). They also demonstrated higher stemcell characteristics where bigger and more spheres were formed in rolling population. In summary, our experimental data have confirmed that cell rolling is a critical step in controlling cancer metastasis, and this novel flow-based device provides a way to capture and enrich metastatic cancer cells in the circulation. This not only leads to identifying the pathways/genes that are responsible for cancer metastasis, but also provides a pure population for preclinical drug screening. It opens up a process for customized cancer treatment which can have more potent action and also reduce the disadvantage of multiple drug side effects.

REFERENCES

1. **Bonnomet A, Brysse A, Tachsidis A, Waltham M, Thompson EW, Polette M, Gilles C.** Epithelial-to-Mesenchymal Transitions and Circulating Tumor Cells. *J Mammary Gland Biol Neoplasia*. 2010 15(2):261-73
2. **Lange PH, Vessella RL** Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. *Cancer Metastasis Rev*. 1998 17:331-336
3. **Sackstein R.** The Bone Marrow Is Akin to Skin: HCELL and the Biology of Hematopoietic Stem Cell Homing. *J. Inv. Derm*. 2004;122:1061- 1069
4. **Dimitroff CJ, Lechpammer M, Long-Woodward D, Kutok JL** Rolling of human bone-metastatic prostate tumor cells on human bone marrow endothelium under shear flow is mediated by E-selectin. *Cancer Research*. 2004 64:5261-5269
5. **Chambers AF, Naumov GN, Varghese HJ, Nadkarni KV, MacDonald IC, Groom AC** Critical steps in hematogenous metastasis: an overview. *Surg Oncol Clin N Am* 2001 10:243-255, vii
6. **Chambers AF, MacDonald IC, Schmidt EE, Koop S, Morris VL, Khokha R, Groom AC** Steps in tumor metastasis: new concepts from intravital videomicroscopy. *Cancer Metastasis Rev* 1995 14:279-301
7. **Chambers AF, Naumov GN, Vantyghem SA, Tuck AB** Molecular biology of breast cancer metastasis. Clinical implications of experimental studies on metastatic inefficiency. *Breast Cancer Res* 2000 2:400-407
8. **Aigner S, Ramos CL, Hafezi-Moghadam A, Lawrence MB, Friederichs J, Altevogt P, Ley K** CD24 mediates rolling of breast carcinoma cells on P-selectin. 1998 *FASEB J* 12:1241-1251
9. **Friederichs J, Zeller Y, Hafezi-Moghadam A, Grone HJ, Ley K, Altevogt P** The CD24/P-selectin binding pathway initiates lung arrest of human A125 adenocarcinoma cells. *Cancer Res* 2000 60:6714-6722
10. **Hanley WD, Burdick MM, Konstantopoulos K, Sackstein R** CD44 on LS174T colon carcinoma cells possesses E-selectin ligand activity. *Cancer Res* 2005 65:5812-5817
11. **Hsu JW, Yasmin-Karim S, King MR, Wojciechowski JC, Mickelsen D, Blair ML, Ting HJ, Ma WL, Lee YF** Suppression of Prostate Cancer Cell Rolling and Adhesion to Endothelium by 1 α ,25-Dihydroxyvitamin D₃. *American Journal of Pathology*. 2011 178(2): 872–880
12. **Malek AM, MD, Alper SL, Izumo S** Hemodynamic Shear Stress and Its Role in Atherosclerosis. *JAMA*. 1999 282(21):2035-2042

B

AUA ANNUAL MEETING
May 19-23, 2012
Atlanta, GA USA

Our knowledge.

Our patients' lives.

MEETING PROGRAM



American
Urological
Association

Education and Research, Inc.

PROSTATE CANCER: BASIC RESEARCH III

B 308 @ Georgia World Congress Center

Moderators: Ralph Buttyan and Alexander Parker

- | ABSTRACT
NUMBER | TITLE | ABSTRACT
NUMBER | TITLE |
|--------------------|---|--------------------|--|
| 469 | IDENTIFICATION OF THE NOVEL PROSTATE CANCER BIOMARKER TDRD1 AS A DIRECT TARGET GENE OF ERG IN PRIMARY PROSTATE CANCER
<i>Joost Boormans*, Hanneke Korsten, Jan Trapman, Rotterdam, Netherlands</i> | 475 | RECIPROCAL REGULATION OF SLUG AND ANDROGEN RECEPTOR FACILITATES PROSTATE CANCER TO ACQUIRE CASTRATION RESISTANT AND STEM-LIKE PHENOTYPES
<i>Kaijie Wu*, Xi'an, China, People's Republic of, Crystal Gore, Dallas, TX, Lin Yang, Xi'an, China, People's Republic of, Gleave Martin, Vancouver, Canada, Rey-Chen Pong, Jer-Tsong Hsieh, Dallas, TX, Dalin He, Xi'an, China, People's Republic of</i> |
| 470 | EXPRESSION OF ERG ONCOPROTEIN IS LESS FREQUENTLY AND ASSOCIATED WITH A LESS AGGRESSIVE TUMOR PHENOTYPE IN JAPANESE PROSTATE CANCER PATIENTS
<i>Takahiro Kimura*, Bungo Furusato, Jun Miki, Toshihiro Yamamoto, Hiroyuki Takahashi, Yuko Kamata, Tokyo, Japan, Geert J.H.L. van Leenders, Rotterdam, Netherlands, Tapio Visakorpi, Tampere, Finland, Shin Egawa, Tokyo, Japan</i> | 476 | CAPTURE AND ANALYSIS OF PROSTATE CANCER STEM CELLS USING A MICROCIRCULATORY CHANNEL
<i>Sayed Yasmin-Karim*, Huel-Ju Ting, Rochester, NY, Michael King, Ithaca, NY, Edward Messing, Yi-Fen Lee, Rochester, NY</i> |
| 471 | DISTINGUISHING FEATURES OF ERG ONCOPROTEIN EXPRESSION AMONG MATCHED COHORTS OF AFRICAN-AMERICAN AND CAUCASIAN-AMERICAN PROSTATE CANCER PATIENTS
<i>Philip Rosen*, Bethesda, MD, David Pfister, Aachen, Germany, Denise Young, Gyorgy Petrovics, Yongmei Chen, Albert Dobi, Rockville, MD, David McLeod, Bethesda, MD, Shiv Srivastava, Rockville, MD, Isabell Sesterhenn, Silver Spring, MD</i> | 477 | LONG CHAIN ACYL-COA SYNTHETASE 3 PLAYS AN IMPORTANT ROLE IN PROSTATE CANCER PROGRESSION: ITS DIRECT REGULATION BY ANDROGEN RECEPTOR AND OCT1
<i>Daisuke Obinata*, Toshiro Migita, Ken-ichi Takayama, Tomohiko Urano, Taro Murata, Tetsuya Fujimura, Satoshi Inoue, Satoru Takahashi, Tokyo, Japan</i> |
| 472 | PROSTATE CANCER RISK ALLELES ARE PRESENT AT SIGNIFICANTLY DIFFERENT FREQUENCIES IN HEALTHY VOLUNTEERS OF DIFFERENT RACES
<i>Qiaoyan Hu*, Brian T. Helfand, Chicago, IL, Stacy Loeb, New York, NY, Nikki Baumann, Rochester, MN, William J. Catalona, Chicago, IL</i> | 478 | COMBINATION OF SLCO1B3 AND SLCO2B1 POLYMORPHISM CAN PREDICT THE DURATION OF THE RESPONSE TO ANDROGEN DEPRIVATION THERAPY IN ADVANCED PROSTATE CANCER.
<i>Naohiro Fujimoto*, Tatsuhiko Kubo, Hoai Bui, Takeshi Yoshida, Kitakyushu, Japan, Hisato Inatomi, Munakata, Japan, Tetsuro Matsumoto, Kitakyushu, Japan</i> |
| 473 | DIFFERENTIAL GENE EXPRESSION PROFILING IN PROLIFERATIVE INFLAMMATORY ATROPHIA COMPARED TO PROSTATE CARCINOMA AND HIGH GRADE PROSTATIC INTRANEOPLASIA USING FROZEN MICRODISSECTED TISSUES
<i>Maria T. Quiles, Maria A. Arbós, Ines de Torres, Carmen Blázquez, Jaume Reventós, Juan Morote*, Barcelona, Spain</i> | 479 | IS INFILTRATION OF TUMOR-ASSOCIATED MACROPHAGES PREDICTIVE OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY?
<i>Kiran Gollapudi*, Colette Galet, Tristan Grogan, Hong Zhang, Jiaoti Huang, David Elashoff, Los Angeles, CA, Leah Gerber, Stephen Freedland, Durham, NC, Matthew Rettig, William Aronson, Los Angeles, CA</i> |
| 474 | PROTEOMIC PROFILING OF EXOSOMES REVEALS NOVEL CANDIDATE MARKERS FOR PROSTATE CANCER
<i>Diederick Duijvesz*, Mirella S. Vredenburgt-van den Berg, A. Marije Hoogland, Rotterdam, Netherlands, Marina A. Gritsenko, Kristin E. Burnum, Richland, WA, Theo M. Luider, Geert L.H.J. van Leenders, Rotterdam, Netherlands, Ljiljana Pasa-Tolic, Richland, WA, Chris H. Bangma, Guido Jenster, Rotterdam, Netherlands</i> | 480 | EXPRESSION OF GANGLIOSIDES, GD1A AND SIALYL PARAGLOBOSIDE, IS REGULATED BY NF-κB-DEPENDENT TRANSCRIPTIONAL CONTROL OF α2,3-SIALYLTRANSFERASE I, II AND VI IN HUMAN CASTRATION-RESISTANT PROSTATE CANCER CELLS
<i>Koji Hatano*, Yasutomo Nakai, Suita, Japan, Yasuhide Miyamoto, Osaka, Japan, Yasufumi Kaneda, Norio Nonomura, Suita, Japan</i> |

Certificate of Attendance

This certifies that

Sayed Yasmin-Karim

has participated in the 2012 Annual Meeting of the
American Urological Association
in Atlanta, GA
May 19-23, 2012



American
Urological
Association

Education and Research, Inc.

Michael T. Sheppard, Executive Director

The American Urological Association Education and Research, Inc. (AUAER) designates this live activity for a maximum of 56.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Accreditation:

The American Urological Association Education and Research, Inc. (AUAER) is accredited by
the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The AUAER takes responsibility for the content, quality and scientific integrity of the CME activity.